SCHEDULE 13G/A: BlackRock Maintains Significant 9.3% Stake in Amicus Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.3% beneficial ownership stake in Amicus Therapeutics Inc. as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 27,904,336 shares of Amicus Therapeutics Inc. common stock.
- This represents 9.3% of the outstanding common stock of Amicus Therapeutics Inc.
- The filing, Amendment No. 9 to Schedule 13G, was submitted on February 5, 2025, with the event date requiring the filing being December 31, 2024.
- BlackRock holds sole voting power over 26,899,351 shares and sole dispositive power over 27,904,336 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Amicus Therapeutics Inc.
- BlackRock, Inc. is identified as a parent holding company or control person, filing under Rule 13d-1(b)(1)(ii)(G).
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership by a major institutional investor, BlackRock, Inc. It indicates continued significant investment in Amicus Therapeutics, which can be viewed as a neutral to slightly positive signal of institutional confidence, but it does not contain new operational or financial performance information.
Positives
- BlackRock, a major institutional investor, maintains a significant 9.3% stake in Amicus Therapeutics, indicating continued investment and potential confidence in the company's long-term prospects.
Negatives
- NA (No specific negatives about Amicus Therapeutics' performance or outlook are disclosed in this ownership filing.)
Risks
- NA (This filing primarily reports beneficial ownership and does not detail specific operational or financial risks related to Amicus Therapeutics Inc.)
Future Outlook
NA (This Schedule 13G filing pertains to beneficial ownership and does not provide forward-looking statements or guidance regarding Amicus Therapeutics Inc.'s future outlook.)
Industry Context
This filing indicates a significant institutional investment in Amicus Therapeutics, a company operating in the biotechnology sector. Large stakes by asset managers like BlackRock are common and reflect their portfolio management strategies across various industries, including healthcare and pharmaceuticals. This type of filing provides transparency on major institutional holdings.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
- Investors: Offers insight into institutional positioning in Amicus Therapeutics, confirming continued interest from a major asset manager.
Next Steps
- NA (This filing does not outline specific future actions or milestones for Amicus Therapeutics Inc.)
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previously revoked Power of Attorney for BlackRock, Inc. |
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date). |
| 01/21/2025 | Date of execution of the new Power of Attorney for BlackRock, Inc. |
| 02/05/2025 | Date of filing of this Schedule 13G. |
Recommendation
holdKeywords
Amicus Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.